Highlights & Basics
- Blepharitis is a significant cause of ocular discomfort, causing foreign body sensation, burning, itching, and crusting around eyelashes.
- Typical findings include lid erythema, collarettes around eyelashes, and capped meibomian glands. Severe disease is associated with corneal changes (e.g., neovascularization, scarring, ulceration, and perforation) that can lead to visual impairment.
- Bacteria, Demodex mites, and meibomian gland dysfunction are important causes of blepharitis.
- Treatment is directed at maintaining eyelid hygiene and may require the use of topical corticosteroids, topical or oral antibiotics, and topical antiparasitics.
- Treatment of associated or underlying medical conditions is essential for the successful management of blepharitis.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Lin A, Ahmad S, Amescua G, et al. Blepharitis preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P50-86.[Full Text]
American Academy of Ophthalmology. Cornea/external disease summary benchmarks - 2023. Dec 2023 [internet publication].[Full Text]
1. Lin A, Ahmad S, Amescua G, et al. Blepharitis preferred practice pattern®. Ophthalmology. 2024 Apr;131(4):P50-86.[Full Text]
2. McCulley JP, Dougherty JM, Deneau DG. Classification of chronic blepharitis. Ophthalmology. 1982 Oct;89(10):1173-80.[Abstract]
3. McCulley JP, Sciallis GF. Meibomian keratoconjunctivitis. Am J Ophthalmol. 1977 Dec;84(6):788-93.[Abstract]
4. Stone DU, Chodosh J. Ocular rosacea: an update on pathogenesis and therapy. Curr Opin Ophthalmol. 2004 Dec;15(6):499-502.[Abstract]
5. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol. 1996 Mar-Apr;40(5):343-67.[Abstract]
6. Lemp MA, Nichols KK. Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul Surf. 2009 Apr;7(2 suppl):S1-S14.[Abstract][Full Text]
7. Lemp MA, Crews LA, Bron AJ, et al. Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea. 2012 May;31(5):472-8.[Abstract]
8. Rim TH, Kang MJ, Choi M, et al. Ten-year incidence and prevalence of clinically diagnosed blepharitis in South Korea: a nationwide population-based cohort study. Clin Exp Ophthalmol. 2017 Jul;45(5):448-454.[Abstract][Full Text]
9. Boel C, Westerveld E, Kloos D, et al. Refining the diagnostic technique to determine prevalence of Demodex mites in eyelash hair follicles within standard ophthalmic practice: a single-center outpatient clinical study. Clin Ophthalmol. 2023;17:2027-36.[Abstract][Full Text]
10. Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign. Clin Ophthalmol. 2022;16:1153-64.[Abstract][Full Text]
11. Dougherty JM, McCulley JP. Comparative bacteriology of chronic blepharitis. Br J Ophthalmol. 1984 Aug;68(8):524-8.[Abstract][Full Text]
12. Groden LR, Murphy B, Rodnite J, et al. Lid flora in blepharitis. Cornea. 1991 Jan;10(1):50-3.[Abstract]
13. Thygeson P. Etiology and treatment of blepharitis. Arch Ophthalmol. 1946 Oct;36(4):445-77.
14. Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology. 2017 Nov;124(11s):S20-6.[Abstract][Full Text]
15. Schaumberg DA, Nichols JJ, Papas EB, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Invest Ophthalmol Vis Sci. 2011 Mar;52(4):1994-2005.[Abstract][Full Text]
16. Luo X, Li J, Chen C, et al. Ocular demodicosis as a potential cause of ocular surface inflammation. Cornea. 2017 Nov;36 Suppl 1(suppl 1):S9-14.[Abstract]
17. Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010 Oct;10(5):505-10.[Abstract]
18. Biernat MM, Rusiecka-Ziółkowska J, Piątkowska E, et al. Occurrence of Demodex species in patients with blepharitis and in healthy individuals: a 10-year observational study. Jpn J Ophthalmol. 2018 Nov;62(6):628-33.[Abstract]
19. Udomwech L, Phasuk N. Multiple eyelid signs are suggestive of Demodex infestation. Clin Ophthalmol. 2021 Feb 17;15:671-8.[Abstract][Full Text]
20. Putnam CM. Diagnosis and management of blepharitis: an optometrist's perspective. Clin Optom (Auckl). 2016 Aug 8;8:71-8.[Abstract][Full Text]
21. Dougherty JM, McCulley JP. Bacterial lipases and chronic blepharitis. Invest Ophthalmol Vis Sci. 1986;27(4):486-91.[Abstract][Full Text]
22. Shine WE, Silvany R, McCulley JP. Relation of cholesterol-stimulated Staphylococcus aureus growth to chronic blepharitis. Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2291-6.[Abstract][Full Text]
23. Ficker L, Ramakrishnan M, Seal D, et al. Role of cell-mediated immunity to staphylococci in blepharitis. Am J Ophthalmol. 1991 Apr 15;111(4):473-9.[Abstract]
24. Amano S, Shimazaki J, Yokoi N, et al. Meibomian gland dysfunction Clinical Practice Guidelines. Jpn J Ophthalmol. 2023 Jul;67(4):448-539.[Abstract][Full Text]
25. Mathers WD, Shields WJ, Sachdev MS, et al. Meibomian gland dysfunction in chronic blepharitis. Cornea. 1991 Jul;10(4):277-85.[Abstract]
26. Jester JV, Nicolaides N, Smith RE. Meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 1989 May;30(5):927-35.[Abstract][Full Text]
27. Dougherty JM, McCulley JP. Analysis of the free fatty acid component of meibomian secretions in chronic blepharitis. Invest Ophthalmol Vis Sci. 1986 Jan;27(1):52-6.[Abstract][Full Text]
28. Shine WE, McCulley JP. The role of cholesterol in chronic blepharitis. Invest Ophthalmol Vis Sci. 1991 Jul;32(8):2272-80.[Abstract][Full Text]
29. Shine WE, McCulley JP. Meibomianitis: polar lipid abnormalities. Cornea. 2004 Nov;23(8):781-3.[Abstract]
30. Shah PP, Stein RL, Perry HD. Update on the management of Demodex blepharitis. Cornea. 2022 Aug 1;41(8):934-9.[Abstract]
31. Zeytun E, Karakurt Y. Prevalence and load of Demodex folliculorum and Demodex brevis (Acari: Demodicidae) in patients with chronic blepharitis in the province of Erzincan, Turkey. J Med Entomol. 2019 Jan 8;56(1):2-9.[Abstract][Full Text]
32. IMS America. National disease and therapeutic index. Ambler, PA: IMS America, Ltd., 1984.
33. Akpek EK, Polcharoen W, Chan R, et al. Ocular surface neoplasia masquerading as chronic blepharoconjunctivitis. Cornea. 1999 May;18(3):282-8.[Abstract]
34. Brownstein B, Codere F, Jackson WB. Masquerade syndrome. Ophthalmology. 1980 Mar;87(3):259-62.
35. Gao YY, Di Pascuale M, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005 Sep;46(9):3089-94.[Abstract][Full Text]
36. Ayres BD, Donnenfeld E, Farid M, et al. Clinical diagnosis and management of Demodex blepharitis: the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH). Eye (Lond). 2023 Oct;37(15):3249-55.[Abstract][Full Text]
37. American Academy of Ophthalmology. Cornea/external disease summary benchmarks - 2023. Dec 2023 [internet publication].[Full Text]
38. Key JE. A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J. 1996 Jul;22(3):209-12.[Abstract]
39. Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008;106:336-56.[Abstract][Full Text]
40. Dry Eye Assessment and Management Study Research Group., Asbell PA, Maguire MG, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med. 2018 May 3;378(18):1681-1690.[Abstract][Full Text]
41. Bowman RW, Dougherty JM, McCulley JP. Chronic blepharitis and dry eyes. Int Ophthalmol Clin. 1987 Spring;27(1):27-35.[Abstract]
42. Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006 Feb;25(2):171-5.[Abstract]
43. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012 May 16;(5):CD005556.[Abstract][Full Text]
44. O'Gallagher M, Bunce C, Hingorani M et al. Topical treatment for blepharokeratoconjunctivitis (BKC) in children. Cochrane Database Syst Rev. 2017 Feb 7;2:CD011965.[Full Text]
45. Smolin G, Okumoto M. Staphylococcal blepharitis. Arch Ophthalmol. 1977 May;95(5):812-6.[Abstract]
46. Tao T, Tao L. Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin. Eye (Lond). 2020 Oct;34(10):1797-808.[Abstract][Full Text]
47. Dursun K, Kim MC, Solomon A, et al. Treatment of recalcitrant recurrent corneal erosions with inhibitors of matrix metalloproteinase-9, doxycycline, and corticosteroids. Am J Ophthalmol. 2001 Jul;132(1):8-13.[Abstract]
48. Farid M, Ayres BD, Donnenfeld E, et al. Delphi panel consensus regarding current clinical practice management options for Demodex blepharitis. Clin Ophthalmol. 2023;17:667-79.[Abstract][Full Text]
49. Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. Cochrane Database Syst Rev. 2020 Jun 20;6:CD013333.[Abstract][Full Text]
50. Lam NSK, Long XX, Li X, et al. Comparison of the efficacy of tea tree (Melaleuca alternifolia) oil with other current pharmacological management in human demodicosis: a systematic review. Parasitology. 2020 Dec;147(14):1587-613.[Abstract][Full Text]
51. Tharmarajah B, Coroneo MT. Corneal effects of tea tree oil. Cornea. 2021 Oct 1;40(10):1363-4.[Abstract]
52. Yeu E, Wirta DL, Karpecki P, et al. Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1). Cornea. 2023 Apr 1;42(4):435-43.[Abstract][Full Text]
53. Gaddie IB, Donnenfeld ED, Karpecki P, et al. Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 trial (Saturn-2). Ophthalmology. 2023 Oct;130(10):1015-23.[Abstract][Full Text]
54. Yeu E, Holdbrook M, Baba SN, et al. Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle. Ocul Immunol Inflamm. 2023 Oct;31(8):1653-61.[Abstract][Full Text]
55. Onghanseng N, Ng SM, Halim MS, et al. Oral antibiotics for chronic blepharitis. Cochrane Database Syst Rev. 2021 Jun 9;6(6):CD013697.[Abstract][Full Text]
56. Gruber GC, Callen JP. Systemic complications of commonly used dermatologic drugs. Cutis. 1978 Jun;21(6):825-9.[Abstract]
57. American Academy of Ophthalmology. Referral of persons with possible eye diseases or injury - 2014. 2014 [internet publication].[Full Text]
58. Tauber J, Berdy GJ, Wirta DL, et al. NOV03 for dry eye disease associated with meibomian gland dysfunction: results of the randomized phase 3 GOBI study. Ophthalmology. 2023 May;130(5):516-24.[Abstract][Full Text]
59. Sheppard JD, Kurata F, Epitropoulos AT, et al. NOV03 for signs and symptoms of dry eye disease associated with meibomian gland dysfunction: the randomized phase 3 MOJAVE study. Am J Ophthalmol. 2023 Aug;252:265-74.[Abstract][Full Text]
